Business
Vor Names Biotech Vet Robert Ang President & CEO
Vor Names Biotech Vet Robert Ang President & CEO.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 1723I PureTech Health PLC 07 August 2019 \n\n7 August 2019 \nPureTech Health plc\n \nPureTech Affiliate Vor Biopharma Appoints Robert Ang, MBBS, MBA, as President and Chief Executive Officer\nPureTech Health plc (LSE: PRTC) (\"PureTech\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliate Vor Biopharma has appointed Robert Ang, MBBS, MBA, as president and chief executive officer.\n \nDr Ang joins Vor Biopharma from Neon Therapeutics (Nasdaq: NTGN), where he served as chief business officer and helped to establish the company prior to its Series A financing and through its initial public offering as an early member of the team. His deep experience in biotech business development also includes his tenure as senior vice president of business development at Bavarian Nordic, where he was primarily responsible for conducting a $975 million transaction with Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset. Dr Ang has also held leadership roles at Cadence Pharmaceuticals and Frazier Healthcare Ventures, a leading life sciences venture capital firm.\n \nBharatt Chowrira, JD, PhD, president and chief of business strategy at PureTech and a member of the board of directors of Vor Biopharma said: \"Dr Ang's extensive industry and business development experience positions him as an exceptional addition to Vor's team. We look forward to working with him as Vor advances its lead candidate for the potential treatment of acute myeloid leukaemia.\" \n \nVor also announced its expansion and move into new integrated offices and lab space in Cambridge, Mass. \nThe full text of the announcement from Vor Biopharma is as follows:\n \nVor Biopharma Appoints Veteran Biotech Executive Dr Robert Ang as President and Chief Executive Officer\n \nCompany expands into integrated labs and offices in global biotech hub of Kendall Square\n \nCAMBRIDGE, August 7, 2019 - Vor Biopharma, an oncology company pioneering engineered haematopoietic stem cells (eHSCs) for the treatment of haematological cancers, today announced the appointment of Robert Ang, MBBS, MBA as its president and chief executive officer. Vor also announced a move into new integrated headquarters in Cambridge, Mass. T...